MRK logo Merck & Co. +
Merck & Co.
+

Merck & Co. (MRK) Business News

Track Merck & Co. in real time with a live news feed covering Merck & Co. stock news, official press releases, company announcements, and an archive of historical Merck & Co. news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
6:45 AM | Thursday | Aug 6, 2026 Business Wire

U.S. FDA Accepts sBLA for ENFLONSIAâ„¢ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

News Thumbnail
6:30 AM | Tuesday | Aug 4, 2026 Business Wire

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

News Thumbnail
11:04 AM | Wednesday | Jul 29, 2026 Business Wire

Merck Announces Fourth-Quarter 2026 Dividend

News Thumbnail
6:45 AM | Friday | Jul 24, 2026 Business Wire

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

News Thumbnail
6:45 AM | Thursday | Jul 16, 2026 Business Wire

Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

News Thumbnail
7:00 AM | Wednesday | Jul 15, 2026 Business Wire

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

News Thumbnail
6:45 AM | Wednesday | Jul 1, 2026 Business Wire

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

News Thumbnail
6:45 AM | Monday | Jun 29, 2026 Business Wire

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

News Thumbnail
6:45 AM | Thursday | Jun 25, 2026 Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

News Thumbnail
6:45 AM | Monday | Jun 22, 2026 Business Wire

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

News Thumbnail

U.S. FDA Accepts sBLA for ENFLONSIAâ„¢ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Business Wire

6:45 AM | Thursday | Aug 6, 2026

news photo
Loading...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIAâ„¢ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.

Read full article redirect
6:45 AM | Thursday | Aug 6, 2026

U.S. FDA Accepts sBLA for ENFLONSIAâ„¢ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIAâ„¢ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.

Read full article arrow
News Thumbnail
6:30 AM | Tuesday | Aug 4, 2026

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.
J., USA Announces Second-Quarter 2026 Financial Results.

Read full article arrow
News Thumbnail
11:04 AM | Wednesday | Jul 29, 2026

Merck Announces Fourth-Quarter 2026 Dividend

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Fourth-Quarter Dividend.

Read full article arrow
News Thumbnail
6:45 AM | Friday | Jul 24, 2026

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Voluntary licensing agreements cover 129 countries in regions which account for the substantial majority of new HIV diagnoses globally.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Jul 16, 2026

Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck's LIPFENDRA is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia.

Read full article arrow
News Thumbnail
7:00 AM | Wednesday | Jul 15, 2026

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026.

Read full article arrow
News Thumbnail
6:45 AM | Wednesday | Jul 1, 2026

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4.

Read full article arrow
News Thumbnail
6:45 AM | Monday | Jun 29, 2026

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Jun 25, 2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead's Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative.

Read full article arrow
News Thumbnail
6:45 AM | Monday | Jun 22, 2026

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderately to severely active UC. The study successfully met its primary endpoint of clinical remission according to the Modified Mayo Scor.

Read full article arrow
News Thumbnail